Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review

Ruizheng Sun; Ranran Wang; Siyuan Chang; Kexin Li; Rongsi Sun; Mengnan Wang; Zheng Li

doi:10.3389/fphar.2019.01457

Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review

Front Pharmacol. 2019 Dec 18:10:1457. doi: 10.3389/fphar.2019.01457. eCollection 2019.

Authors

Ruizheng Sun^{1

2

3}, Ranran Wang⁴, Siyuan Chang^{1

2

3}, Kexin Li^{1

2

3}, Rongsi Sun^{1

2

3}, Mengnan Wang^{1

2

3}, Zheng Li^{1

2

3}

Affiliations

¹ Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
² NHC Key Laboratory of Carcinogenesis, Cancer Research Institute and School of Basic Medical, Central South University, Changsha, China.
³ The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, China.
⁴ Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

Abstract

Lung cancer is one of main causes of cancer mortality and 83% of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Patients with NSCLC usually have a poor prognosis and one of the leading causes is drug resistance. With the progress of drug therapy, the emergence and development of drug resistance affected the prognosis of patients severely. Accumulating evidence reveals that long non-coding RNAs (lncRNAs), as "dark matters" of the human genome, is of great significance to drug resistance in NSCLC. Herein, we review the role of lncRNAs in drug resistance in NSCLC.

Keywords: cisplatin; drug resistance; epidermal growth factor receptor tyrosine kinase inhibitors; immune checkpoint inhibitors; long non-coding RNAs; non-small cell lung cancer; taxanes.

Publication types

Review